What is BillionToOne?
Headquartered in Menlo Park, California, BillionToOne is at the forefront of precision diagnostics, aiming to enhance the accuracy, efficiency, and accessibility of molecular testing. The company's proprietary QCT molecular counter platform is distinguished by its unique ability to count DNA molecules down to the single-count level. Its flagship product, UNITY, offers a noninvasive prenatal screening solution that analyzes fetal cell-free DNA from maternal blood to detect conditions such as cystic fibrosis (CF), spinal muscular atrophy (SMA), and hemoglobinopathies. This innovative approach positions BillionToOne as a key player in the rapidly evolving diagnostics market.
How much funding has BillionToOne raised?
BillionToOne has raised a total of $646.6M across 6 funding rounds:
Series A
$15M
Series B
$55M
Series C
$125M
Unspecified
$48.5M
Series D
$130M
IPO
$273.1M
Series A (2019): $15M with participation from 500 Startups Istanbul, Libertus Capital, NeoTribe Ventures, HOF Capital, Y Combinator, Civilization Ventures, Pacific 8 Ventures, and Hummingbird Ventures
Series B (2021): $55M, investors not publicly disclosed
Series C (2022): $125M supported by Neotribe Ventures, Adams Street Partners, Baillie Gifford, and Hummingbird Ventures
Unspecified (2022): $48.5M featuring Baillie Gifford, Neotribe Ventures, Adams Street Partners, Hummingbird Ventures, and Libertus Capital
Series D (2024): $130M, investors not publicly disclosed
IPO (2025): $273.1M, investors not publicly disclosed
Key Investors in BillionToOne
Baillie Gifford
Baillie Gifford is an investment management firm founded in Edinburgh in 1908, specializing in investment advice and managing assets globally.
Neotribe Ventures
Neotribe Ventures is a Silicon Valley-based venture capital firm focused on identifying and funding entrepreneurs developing breakthrough technologies with the potential for transformative market movements.
Adams Street Partners
Founded in 1972, Adams Street Partners provides investment management services in private markets worldwide, with its headquarters located in Chicago, Illinois.
What's next for BillionToOne?
The substantial enterprise-level funding and recent strategic investment indicate a strong growth trajectory for BillionToOne. This capital infusion is expected to fuel further development of its QCT platform and expand the reach of its UNITY product. The company is likely to focus on scaling its operations, enhancing its commercialization efforts, and potentially exploring new diagnostic applications. Strategic partnerships and continued innovation will be crucial as BillionToOne aims to solidify its market position and achieve its mission of making advanced molecular diagnostics universally accessible.
See full BillionToOne company page
